TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32806711

Group type: EXPERIMENTAL
Intervention: 5 g of Leucine-Enriched Essential Amino Acids (LEAA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 34228018

Group type: EXPERIMENTAL
Intervention: Nurse home visits postdischarge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term focused feedback
Number of subjects: 0
Study: 35178112

Group type: EXPERIMENTAL
Intervention: Multitasking Test (MTT)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Rapid Visual Information Processing (RVP)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Paired Associates Learning (PAL)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combination of MTT and RVP
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Education added to models
Number of subjects: 105
Study: 33350698

Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32312284

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34152055

Group type: EXPERIMENTAL
Intervention: Tasimelteon 20 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Zopiclone 7.5 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 32790196

Group type: EXPERIMENTAL
Intervention: High-dose teriparatide (40 μg)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard-dose teriparatide (20 μg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 69
Study: 36323490

Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg two times per day
Number of subjects: 4362

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg two times per day
Number of subjects: 4362

Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 4362

Group type: COMPARATOR
Intervention: D-dimer
Number of subjects: 4362
Study: 33826563

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA) at a new dosing regimen (10 mg/kg load, 5 mg/kg/h infusion)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 90
Study: 33003132

Group type: EXPERIMENTAL
Intervention: McGrath MAC (McG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Storz C‐MAC PM (ST)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 50
Study: 32271182

Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Femoral Triangle Block (FTB)
Number of subjects: 60
Study: 36881400

Group type: EXPERIMENTAL
Intervention: Investigator Reports (IR)
Number of subjects: 841

Group type: COMPARATOR
Intervention: Clinical Events Committee (CEC)
Number of subjects: 841
Study: 32748570

Group type: EXPERIMENTAL
Intervention: Lafenta transdermal fentanyl patch (11.0 mg)
Number of subjects: 2
Study: 36400984

Group type: EXPERIMENTAL
Intervention: NIV with active humidification
Number of subjects: 182

Group type: COMPARATOR
Intervention: HFNC
Number of subjects: 182
Study: 33225426

Group type: EXPERIMENTAL
Intervention: Well-expanded stents (≥90%)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Under-expanded stents (<90%)
Number of subjects: 151
Study: 35756957

Group type: EXPERIMENTAL
Intervention: Neem chip (10% absorbable)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Soft tissue diode laser
Number of subjects: 14

Group type: COMPARATOR
Intervention: Phase I therapy alone
Number of subjects: 14
Study: 34619639

Group type: EXPERIMENTAL
Intervention: Albuminuria
Number of subjects: 480698
Study: 34333190

Group type: EXPERIMENTAL
Intervention: Japanese cedar pollen sublingual immunotherapy (SLIT) tablets (5000 Japanese Allergy Units)
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1042
Study: 36114800

Group type: EXPERIMENTAL
Intervention: Decision-aid (DA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Informative brochure
Number of subjects: 0
Study: 33285016

Group type: EXPERIMENTAL
Intervention: Mindful awareness component
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Distress tolerance component
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Emotion modulation component
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Values-based decision making component
Number of subjects: 256
Study: 36345029

Group type: EXPERIMENTAL
Intervention: Virtual simulation experimental teaching model
Number of subjects: 199

Group type: COMPARATOR
Intervention: Conventional teaching mode
Number of subjects: 199
Study: 35969429

Group type: EXPERIMENTAL
Intervention: Health education through CKD awareness campaign and mobile health technologies
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 126
Study: 32078947

Group type: EXPERIMENTAL
Intervention: Upright posture
Number of subjects: 54

Group type: COMPARATOR
Intervention: Stooped posture
Number of subjects: 54
Study: 33579762

Group type: EXPERIMENTAL
Intervention: HOLOBalance
Number of subjects: 120

Group type: COMPARATOR
Intervention: OTAGO Home Exercise Programme
Number of subjects: 120
Study: 36259401

Group type: EXPERIMENTAL
Intervention: E-learning session
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Workshop instruction activity
Number of subjects: 0
Study: 34191352

Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg/d
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Solriamfetol 75 mg/d, 150 mg/d, 300 mg/d
Number of subjects: 66
Study: 36084494

Group type: EXPERIMENTAL
Intervention: Solriamfetol 37.5 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solriamfetol 75 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solriamfetol (all doses combined)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33318635

Group type: EXPERIMENTAL
Intervention: AV-101 (1440 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AV-101 (720 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AV-101 (720 mg and 1440 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 36461655

Group type: EXPERIMENTAL
Intervention: Bayesian-guided AUC0-24h/MIC
Number of subjects: 45

Group type: COMPARATOR
Intervention: Trough level monitoring
Number of subjects: 45
Study: 32260047

Group type: EXPERIMENTAL
Intervention: Equine-assisted intervention (riding once a week, led by a certified therapist)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group Passive (lacked regular activities outside the home)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group Active (had several activities outside the home per week)
Number of subjects: 14
Study: 34271944

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with weight loss
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Mediterranean diet without weight loss
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (face to face)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Remote data collection (group 3)
Number of subjects: 185
Study: 35358462

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician's choice of next-generation hormonal drug
Number of subjects: 0
Study: 34421801

Group type: EXPERIMENTAL
Intervention: Combined resistance and endurance training (EXP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 27
Study: 32581112

Group type: EXPERIMENTAL
Intervention: Polygenic hazard score (PHS) informed screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: PSA testing
Number of subjects: 0
Study: 32919388

Group type: EXPERIMENTAL
Intervention: XtraMath® (math training)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Cogmed® (active control condition; working memory)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: XtraMath®
Number of subjects: 65
Study: 32487213

Group type: EXPERIMENTAL
Intervention: Post-operative placebo therapy (ceftriaxone 2 g/24 h and metronidazole 1500 mg/24 h for 3 days)
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Post-operative antibiotic therapy (ceftriaxone 2 g/24 h and metronidazole 1500 mg/24 h for 3 days)
Number of subjects: 1494
Study: 34405414

Group type: EXPERIMENTAL
Intervention: Design-thinking based education program
Number of subjects: 105
Study: 34004339

Group type: EXPERIMENTAL
Intervention: Follow-up publications with different primary outcomes compared to original RCTs
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Follow-up publications with outcome switches not pre-specified or explained
Number of subjects: 78

Group type: COMPARATOR
Intervention: Initial RCTs with outcome switching
Number of subjects: 78
Study: 32438531

Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF) with 100% or 70% of calculated weekly energy requirements for 8 weeks
Number of subjects: 0
Study: 36195542

Group type: EXPERIMENTAL
Intervention: Volanesorsen, 300 mg weekly for 16 weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Volanesorsen, 300 mg weekly for 32-52 weeks
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 33752216

Group type: EXPERIMENTAL
Intervention: Immediate memory in men
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Postural sway in women
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Hand reaction time in women
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: DTC of gait speed, cadence, and double support time in women
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: DTC of gait speed, step length, and double support time in men
Number of subjects: 492
Study: 33143484

Group type: EXPERIMENTAL
Intervention: Vitamin D and evening primrose oil co-supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34837510

Group type: EXPERIMENTAL
Intervention: High-dose 131I-mIBG therapy (666 MBq/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Single high-dose chemotherapy (HDC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Haematopoietic stem cell transplantation (HSCT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Response according to RECIST 1.1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scintigraphic response
Number of subjects: 8
Study: 32675541

Group type: EXPERIMENTAL
Intervention: Elective Sigmoid Resection within 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative Management
Number of subjects: 0
Study: 36336337

Group type: EXPERIMENTAL
Intervention: Imagery training with an avatar in VR
Number of subjects: 30

Group type: COMPARATOR
Intervention: VR without an avatar (Control)
Number of subjects: 30
Study: 32578488

Group type: EXPERIMENTAL
Intervention: Capsifen (200 mg × 1/day, 4 mg capsaicinoids/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Capsifen
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 32860783

Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL) group
Number of subjects: 122

Group type: COMPARATOR
Intervention: Traditional teaching methods group
Number of subjects: 122
Study: 34176370

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) with blue-light-reducing features activated
Number of subjects: 55

Group type: COMPARATOR
Intervention: Active Control Group (ACG) with no blue-light-reducing features
Number of subjects: 55
Study: 34972765

Group type: EXPERIMENTAL
Intervention: Benznidazole (BZN) and Nifurtimox (NFX) chemotherapy regimens
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard-of-care (SoC) BZN and NFX
Number of subjects: 450
Study: 34602021

Group type: EXPERIMENTAL
Intervention: Trunk and lower extremity long-axis rotation exercise (20-minute sessions)
Number of subjects: 36
Study: 34964849

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 1279

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1279
Study: 33966880

Group type: EXPERIMENTAL
Intervention: Positive training (90% positive-10% negative)
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: 50% positive-50% negative training
Number of subjects: 807

Group type: COMPARATOR
Intervention: No-training control
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Anxious imagery prime
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Neutral imagery prime
Number of subjects: 807
Study: 32345375

Group type: EXPERIMENTAL
Intervention: Intervention program consisting of detecting symptoms of mental illness, strengthening parenting skills using the Circle of Security Parenting program, supporting breastfeeding, and organizing treatment pathways.
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intervention program
Number of subjects: 76

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 76
Study: 35575051

Group type: EXPERIMENTAL
Intervention: Fractional-dose IPV (fIPV, one-fifth of IPV) - 1 dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fractional-dose IPV (fIPV, one-fifth of IPV) - 2 doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full-dose IPV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full-dose IPV - 2 doses
Number of subjects: 0
Study: 33609248

Group type: EXPERIMENTAL
Intervention: CPX-351 (liposomal daunorubicin and cytarabine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapeutic options
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venetoclax in combination with azacitidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing clinical trials with low- and high-intensity therapies
Number of subjects: 0
Study: 32448020

Group type: EXPERIMENTAL
Intervention: riluzole (50 mg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 37
Study: 36175104

Group type: EXPERIMENTAL
Intervention: Preoperative patient education comprising of a video and prehabilitation programme with standard care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study: 33440997

Group type: EXPERIMENTAL
Intervention: Genetic susceptibility to smoking (measured by a polygenic risk score)
Number of subjects: 408609
Study: 33355781

Group type: EXPERIMENTAL
Intervention: Integrated System (ultrasound-guided and electrocardiogram confirmation)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Anthropometric estimation of device length (Control)
Number of subjects: 165
Study: 35997845

Group type: EXPERIMENTAL
Intervention: Promoting First Relationships® (PFR)
Number of subjects: 162
Study: 33960689

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 13
Study: 32777737

Group type: EXPERIMENTAL
Intervention: Rituximab plus 6 months Mycophenolate mofetil (MMF)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo plus 6 months Mycophenolate mofetil (MMF)
Number of subjects: 122
Study: 34800079

Group type: EXPERIMENTAL
Intervention: Patiromer (titrated up to a maximum of three packs/day, 8.4 g/pack)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Placebo (patiromer withdrawal)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 820
Study: 34563120

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) exercises based on Xbox Kinect, 2 sessions of 30-45 minutes weekly for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine exercises of the nursing homes (Control)
Number of subjects: 60
Study: 36044317

Group type: EXPERIMENTAL
Intervention: IV Aviptadil for 3 days
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 34597975

Group type: EXPERIMENTAL
Intervention: Olaparib alone
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 602

Group type: COMPARATOR
Intervention: Placebo plus bevacizumab
Number of subjects: 602
Study: 32790066

Group type: EXPERIMENTAL
Intervention: 150 mg glasdegib
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 300 mg glasdegib
Number of subjects: 36

Group type: COMPARATOR
Intervention: 400 mg moxifloxacin (positive control)
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 32199696

Group type: EXPERIMENTAL
Intervention: IF 5:2 diet
Number of subjects: 38
Study: 35753072

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) four times weekly (EX; n=20)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (CON; n=10)
Number of subjects: 30
Study: 33765717

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 282
Study: 35794462

Group type: EXPERIMENTAL
Intervention: Peer learning intervention (HBB and ECEB training, 1 day peer learning course, peer practice scenarios, mentorship visits at 2 to 3 and 6 to 7 months)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Peer learning intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (HBB and ECEB training alone)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 34511098

Group type: EXPERIMENTAL
Intervention: 0.454% w/w stannous fluoride toothpaste (Test)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sodium monofluorophosphate toothpaste (Control)
Number of subjects: 130
Study: 32613649

Group type: EXPERIMENTAL
Intervention: dupilumab
Number of subjects: 250

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 250
Study: 35427629

Group type: EXPERIMENTAL
Intervention: RADPAD
Number of subjects: 137

Group type: COMPARATOR
Intervention: No RADPAD
Number of subjects: 137
Study: 34118716

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Buprenorphine (BUP-NX)
Number of subjects: 373
Study: 33066859

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 35534883

Group type: EXPERIMENTAL
Intervention: Longmu Tang granule
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo granule
Number of subjects: 60
Study: 32947383

Group type: EXPERIMENTAL
Intervention: Topical povidone-iodine 10% plus levofloxacin 0.5% at 1 hour preoperatively
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (received PVI just before the operation)
Number of subjects: 142
Study: 35485424

Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 709

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study: 35112661

Group type: EXPERIMENTAL
Intervention: Circuit Resistance Training (CRT)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Non-exercise control session (CTL)
Number of subjects: 7
Study: 33637837

Group type: EXPERIMENTAL
Intervention: Predictive algorithm guided treatment
Number of subjects: 913

Group type: COMPARATOR
Intervention: Treatment as usual (TaU)
Number of subjects: 913
Study: 32162501

Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Concurrent strength and endurance training (SE)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 44
Study: 35510542

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160
Study: 34616464

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg) for two weeks at 10 PM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for two weeks at 10 PM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg)
Number of subjects: 0
Study: 34666693

Group type: EXPERIMENTAL
Intervention: UV irradiation (half-body UV irradiation, twice weekly over 6 months at one standard erythema dose)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: UV irradiation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Vitamin D supplementation (5600 international units of cholecalciferol once a week)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Vitamin D supplementation
Number of subjects: 61
Study: 32913645

Group type: EXPERIMENTAL
Intervention: Intuitive Eating (IE)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Pinned Eating (PE)
Number of subjects: 56
Study: 33546739

Group type: EXPERIMENTAL
Intervention: Baricitinib (4 mg once daily, can be reduced to 2 mg) for 5-7 days
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard of care (including antibiotics, thromboembolic prophylaxis, and possibly remdesivir)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 136
Study: 33046869

Group type: EXPERIMENTAL
Intervention: anti-PD-L1 (durvalumab) plus anti-CTLA-4 (tremelimumab)
Number of subjects: 28
Study: 35187678

Group type: EXPERIMENTAL
Intervention: Rational Emotive Occupational Health Coaching (REOHC)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study: 33963406

Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF) with explicit financial incentives linked to results
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct financing with additional resources available for health providers not linked to performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced supervision and monitoring without additional resources
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36071262

Group type: EXPERIMENTAL
Intervention: Metformin as an adjunct to antidepressants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32044695

Group type: EXPERIMENTAL
Intervention: Balance specific physiotherapy (Motor Program Activating Therapy in Czech cohort and Sensory-motor Integration Training in Italian cohort)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Non-balance specific physiotherapy (Vojta reflex locomotion in Czech cohort and conventional dynamic strengthening exercises in Italian cohort)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Inpatient physiotherapy intensity
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Level of disability
Number of subjects: 149
Study: 35114338

Group type: EXPERIMENTAL
Intervention: Mild moxibustion (MM)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo moxibustion (PM)
Number of subjects: 76